Program

Updated: September 14, 2018

Friday, September 14 | Saturday, September 15 | Sunday, September 16

Guidelines for Poster Presenters (PDF) »



Friday, September 14, 2018

7:30 am Registration is Open
(Grand Ballroom pre-function)
Note: All general sessions are held in the Grand Ballroom Salon I-II
PRE-MEETING –
Clinical Outcomes and Outreach in Cancer Cachexia
Chair: Jose Garcia, MD, PhD – VA Puget Sound and University of Washington, USA
Session A: Clinical Trials and Care in Cancer Cachexia
8:20 am Introductory Remarks
8:30 am Richard Skipworth, MD
University of Edinburgh, United Kingdom
Update on the definition of cancer cachexia and update on clinical trials
9:00 am Egidio Del Fabbro, MD
Virginia Commonwealth University, USA
Practical considerations of running a successful cancer cachexia clinic

9:30 am Vickie Baracos, PhD
University of Alberta, Canada
Evolving inclusion and exclusion criteria in cancer cachexia clinical trials
10:00 am Coffee Break
(Grand Ballroom pre-function)
10:30 am Christopher Hartshorn, PhD, Michael Graham Espey, PhD
National Cancer Institute, USA
Widgets to cancer patient-specific digits: The case for out-of-clinic objective measures and their potential impact to longitudinal discovery in cancer cachexia
11:00 am Julie Stone, PhD
Merck & Co., Inc., USA
Insights into association of cancer cachexia and catabolic clearance with response gained from pembrolizumab exposure-response assessments

11:30 am Andrew Hendifar, MD
Cedars-Sinai Medical Center, USA
Focus on pancreatic cancer cachexia: Clinical trials in progress

This talk is sponsored by Yinuoke Ltd
12:00 pm Panel Discussion
12:30 pm Lunch
(Grand Ballroom pre-function)
Session B: Conversations with Caregivers and Patients
Moderator: Marion Couch, MD, PhD – Indiana University School of Medicine, USA
1:30–3:00 pm Program for Caregivers and Patients
Open to the public; pre-registration required
(Grand Ballroom Salon I-II)
1:30 pm Introductory Remarks
Marion Couch, MD, PhD
Indiana University School of Medicine, USA
1:40 pm Daniel Marks, MD, PhD - Oregon Health & Science University, USA
Denis Guttridge, PhD - Medical University of South Carolina, USA
New concepts
2:00 pm Richard Skipworth, MD
University of Edinburgh, United Kingdom
New potential treatments
2:15 pm Theresa P. Yeo, PhD
Jefferson Pancreas Tumor Registry, USA
Pursuing clinical correlates of cancer cachexia
2:30 pm Martin Kochanczyk, PhD
Luminex Corporation, USA
A family perspective on the effects of cachexia
2:45 pm Audience Questions

2:30–6:00 pm Poster Set Up
(Grand Ballroom Salon III)

Guidelines for Poster Presenters (PDF) »

Session 1 –
Introductory Remarks and Keynote Address
Chair: Vickie Baracos, PhD – University of Alberta, Canada
3:45 pm Introductions to the 4th Cancer Cachexia Conference
Denis Guttridge, PhD
Medical University of South Carolina, USA
4:00 pm Keynote Address
Josep Argiles, PhD
University of Barcelona, Spain
Past, present, and future of cancer cachexia research
5:00 pm Cutting Edge Science in Cancer Cachexia
  Estefania Simoes Fernandez
University of São Paulo, Brazil
Is cachexia associated with altered brain structure? A voxel-based morphometry MRI study in cachectic colorectal cancer patients

Lindsey Anderson, PhD
VA Puget Sound Health Care System, USA
Assessment of functional performance in GI cancer patients with or without weight loss

Ashok Narasimhan, PhD
Indiana University School of Medicine, USA
Do skeletal muscle and adipose tissue have distinct gene expression patterns in PDAC cachexia?

Rodrigo Xavier das Neves, PhD
Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
Gut microbiota and immune cells play a role in adipose tissue wasting during cancer cachexia development

Hamood AlSudais
University of Ottawa, Canada
C/EBPβ regulates the expression of anti-myogenic secreted proteins in cancer cachexia

Michael Deyhle, PhD
University of Florida, USA
Loss of Myocilin induces membrane fragility and skeletal muscle wasting and its overexpression deters muscle wasting in C26 tumor-bearing mice
5:30-7:30 pm Welcoming Reception
(Georgian Room)
7:30 pm Poster Viewing
(Grand Ballroom Salon III)

Dinner and evening on your own


Back to top ...
 

Saturday, September 15, 2018

6:30-8:30 am Breakfast
(Grand Ballroom pre-function)
Note: All general sessions are held in the Grand Ballroom Salon I-II
Session 2 –
Updates on Developing Models of Cancer Cachexia
Chair: Simon Wing, MD – McGill University, Canada
8:30 am Jose Trevino, MD
University of Florida, USA
"The time is now": Necessary changes for research in pancreatic cancer-induced cachexia
9:00 am Swarnali Acharyya, PhD
Columbia University Irving Medical Center, Institute for Cancer Genetics, USA
Role of ZIP14 in promoting cachexia in metastatic cancers
  Selected Short Talks
9:30 am Short Talk 1
David Waning, PhD
Penn State College of Medicine, USA
TBA
9:45 am Short Talk 2
Fabio Penna, PhD
University of Torino, Italy
Autophagy and mitophagy link muscle wasting to impaired function in cancer cachexia
10:00 am Coffee Break
(Grand Ballroom Salon III)
Session 3 –
Mechanisms of Muscle Wasting: Part I
Chair: Paul Gregorevic, PhD – Baker Heart and Diabetes Institute, Australia
10:30 am Yi-Ping Li, PhD
University of Texas Health Science Center, USA
Mechanism of pancreatic cancer induction of muscle wasting
11:00 am Andrew Judge, PhD
University of Florida, USA
Cancer induced muscle pathology and mediators
11:30 pm Marco Sandri, MD
University of Padova, Italy
Novel players in muscle wasting
12:00 pm Lunch
(Georgian Room)
1:15-3:45 pm Poster Viewing
(Grand Ballroom Salon III)
Session 4 –
Organ Cross Talk in Cancer Cachexia
Chair: Richard Skipworth, MD – University of Edinburgh, United Kingdom
4:00 pm Maria Rohm, PhD
Helmholtz Center Munich, Germany
AMPK action in adipose wasting in cancer cachexia
4:30 pm Daniel Marks, MD, PhD
Oregon Health Sciences University, USA
Hypothalamic signaling in regulating muscle loss in cancer cachexia
5:00 pm Bernard Allan, PhD
NGM Biopharmaceuticals Inc., USA
GFRAL-dependent nervous system activation by GDF-15 in anorexia and cachexiar
5:30 pm Marilia Seelaender, PhD
University of São Paulo, Brazil
Cachexia-associated alterations in the gut microbiota of cancer patients: Can exercise restore the balance?
6:00 pm End of program day


Back to top ...
 

Sunday, September 16, 2018

6:30-8:30 am Breakfast
(Grand Ballroom pre-function)
Session 5 –
Analysis of Big Data
Chair: Melinda Sheffield-Moore, PhD – Texas A&M University, USA
8:30 am Ben Zeskind, PhD, MBA
Immuneering Inc., USA
Data-driven identification and optimization of new medicines for cancer cachexia
9:00 am Sambasivarao Damaraju, PhD
University of Alberta, Canada
Genetic signatures in cancer cachexia: "Omics" approaches for mechanistic insights
  Selected Short Talks
9:30 am Short Talk 3
Tianshun Xu, PhD
GlaxoSmithKline, USA
Treatment with an FLRG-Fc fusion protein counteracts cachexia in C-26 tumor bearing mice
9:45 am Short Talk 4
Hannah Wilson
West Virginia University, USA
Dysregulation of peroxisome proliferator-activated receptor signaling is mechanistically central to breast cancer-induced skeletal muscle fatigue
10:00 am Coffee Break
(Grand Ballroom Salon III)
Session 6 –
Next Generation Researchers in Cancer Cachexia
Chairs:
Neil Johns, MD – University of Edinburgh, UK,
Erin Talbert, PhD – Medical University of South Carolina, USA
10:30 am Christopher Coss, PhD
Assistant Professor, The Ohio State University College of Pharmacy, USA
Overcoming resistance to anabolic androgen therapy in the C26 model of experimental cachexia
10:45 am Haiming Liu, PhD
Post Doctoral Fellow, VA Puget Sound and University of Washington Seattle, USA
Ghrelin mitigates cancer-induced muscle atrophy through GHSR-1a-dependent and independent mechanisms
11:00 am Andrea Bonetto, PhD
Assistant Professor, Indiana University, USA
PDK4 drives metabolic alterations and skeletal muscle atrophy in cancer cachexia
11:15 am Daria Neyroud, PhD
Post Doctoral Fellow, University of Florida, USA
Forkhead box P1 (FoxP1) is increased in the skeletal muscle of tumor bearing hosts and sufficient to cause wasting
11:30 am Rishi Jain, MD
Assistant Professor, The Ohio State University, USA
Associations between the pre-enrollment Patient-Generated Subjective Global Assessment (PG-SGA) score and physical activity level with toxicity and outcomes in phase 1 and 2 oncology clinical trials
11:45 am Seyyed Mohammad Reza Kazemi-Bajestani, MD, PhD
Post Doctoral Fellow, University of Alberta, Canada
Concurrent loss of skeletal muscle, fat and heart in cancer cachexia associates with poor functional and clinical outcomes
12:00 pm Lunch
(Georgian Room)
Session 7 –
Mechanisms of Muscle Wasting: Part II
Chair: Paola Costelli, PhD – University of Turin, Italy
1:30 pm Esther Barreiro, PhD
University of Barcelona, Spain
Novel therapeutic strategies in cancer cachexia: Role of PARP and other targets
2:00 pm Teresa Zimmers, PhD
Indiana University School of Medicine, USA
Mechanisms of muscle and bone loss in cancer cachexia
This talk is sponsored by the Indiana Center for Musculoskeletal Health
2:30 pm David Glass, MD
Novartis Institutes for Biomedical Research, USA
Molecular mechanisms regulating muscle mass and mitochondria
3:00 pm Coffee Break
(Grand Ballroom Salon III)
Session 8 –
Identification of Biomarkers in Cancer Cachexia
Chair: David Thomas, MD – Broad Institute, USA
3:30 pm Jean-Paul Thissen, MD, PhD
Université catholique de Louvain, Belgium
High circulating Activin A is associated with cachexia and poor survival in cancer patients
4:00 pm Shyh-Chang Ng, PhD
Chinese Academy of Sciences, China
Fatty acid oxidation during cancer cachexia
  Selected Short Talks
4:30 pm Short Talk 5
Carsten Jacobi, PhD

Novartis Institutes for BioMedical Research Basel, Switerland
Potential novel urine biomarker to monitor changes in muscle mass in cancer cachexia
4:45 pm Short Talk 6
Matthew Bryant Hudson, PhD

University of Delaware, USA
Muscle derived extracellular vesicles as vehicles and biomarkers in muscle wasting
5:00 pm Giuseppina Caretti, PhD
University of Milan, Italy
Epigenetic targeting of BET proteins to ameliorate cancer cachexia
5:30 pm Closing Remarks


Back to top ...